This well attended symposium, co-ordinated by Professor T Macdonald (University of Dundee), brought together leaders in Therapeutics from both the UK and USA. The ‘Cox-2 saga’ was the focal point of the day with presentations by Dr G Fitzgerald and Professor P Dieppe highlighting the issue and producing some lively and engaging debate.
Get full access to this article
View all access options for this article.
References
1.
Maxwell S,Walley T. Teaching safe and effective prescribing in UK medical schools: a core curriculum for tomorrow’s doctors. Br J Clin Pharmacol 2003; 55(6):496–503.
2.
PirmohamedMSJamesMeakinS Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 2004; 329(7456):15–9.
3.
CarlbergBOSamuelssonLindholmLH.Atenolol in hypertension: is it a wise choice? Lancet 2004; 364(9446):1684–9.
4.
DickersonJEADHingoraniMJAshbyCRPalmerBrownMJ.Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353(9169):2008–13.
5.
BombardierCLLaineReicinA Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343(21):1520–8.
6.
FurbergCDBMPsatyParecoxibFitzGerald GA., valdecoxib, and cardiovascular risk. Circulation 2005; 111(3):249.
7.
DieppePCBartlettPDaveyLDoyalEbrahimS. Balancing benefits and harms: the example of non-steroidal antiinflammatory drugs. BMJ 2004; 329(7456):31–4.
8.
DieppePASEbrahimRMMartinJuniP. Lessons from the withdrawal of rofecoxib. BMJ 2004; 329(7471):867–868.
